Reneuron Share Discussion Threads

[rrb] 04/10/2019 09:43

scuba - for rare diseases, the sample size at this stage is always going to be small. Likewise, for unmet needs, which most rare diseases are, you don't need huge numbers to get a therapy through.

Wig - the point i am making is it doesnt change anything for these patients. If you give anyone the choice of 100% probability of blindness vs possibility of some vision, most will choose latter. From a payer perspective, the lack of options makes the cost more worthwhile, in a value based world.

Again, reiterating the fact that there is clearly potential here for something that there are no treatments for. There has to be some value ascribed to that...

[eggy6198] 04/10/2019 09:36

Totally ignoring anything potentially positive in that post and even used the term dead cat bounce for any rise? RENE is high risk high reward. At the moment we dont know about the 2 fails so unlike you i dont feel i can comment.

Otherwise product works never expected perfect but peoduct works.

[wigwammer] 04/10/2019 09:33

With respect scuba, all you appear to be doing is describing the trial process that needs to be undertaken for any drug. The point that a ph2a trial has a small number of participants is pretty standard, and of course it takes time to get to market from that point. But the reason a ph2 asset can carry substantial value now is that the rewards at the other end runs into billions. I suspect that most large pharma companies have a research horizon of 10 years+ - they need to plan well ahead and keep refilling the pipeline. From that perspective, a product that has just completed a ph2a is relatively mature in the context of that cycle.

[wigwammer] 04/10/2019 09:24

Interesting post rrb. I don't think we know yet that the risk is blindness. All we know is there is a risk ofvision loss, but not whether it is permanent or otherwise.

[scubadiverr] 04/10/2019 09:22

The current sample is is 12 is it not? It's so small as current evidence suggests high risk. 2 of the sample have had injuries from the procedure, that's nearly 20%. Inorder to get regulatory approvals to test on a greater sample size they need to prove a positive/benefit risk ratio. They can't just preceded to a phase 3. Without a phase 3 showing adequate positive/benefit risk ratio no licence will be granted to sell the treatment. They will need a sample size of 400+ to establish reliable evidence base. How long has it taken to get to 12 and how well has it gone so far? I do believe in short term price will rise, or dead cat bounce if you like. Great for traders, not for me. At 50p I'm willing to take the gamble, as the procedure will likely become less risky over time. At the current price I'm not interested as too much potential downside. Others can disagree, but please read up on the many pitfalls of getting a medicinal product to market and don't take the uninformed advice of someone who clearly needs the share price to increase.

[rrb] 04/10/2019 09:15

There is limited precedence for 'what is required' when it comes to cell therapies for unmet needs. 3 years ago there were many, many doubters that a $1m+ cell therapy could be approved in leukaemia. But then we saw Kymriah and Yescarta both approved. The initial patient population - kids with refractory ALL - had no other choice. BMTs didnt work. Chemo didnt work. And then CAR-T came along and changed the game.

The point here is there is NOTHING for RP at the moment. Eylea only treats the oedema while the disease continues to progress, culminating in blindness. The data from RENE suggest that this therapy could work best for patients whose disease has progressed to clinical blindness. At this point, there is no option currently. Eylea has no effect. BUT, we have something here that could potentially help these people. The downside is blindness related to surgery. But these patients are ALREADY CLINICALLY BLIND.

So, again, tell me if this 'potential' is worth more than £50m in mcap for the company, forgetting about the other pipeline prospects.

As always, do what you are comfortable with. All this ramping/deramping debate is unnecessary. There are clearly a lot of clueless people on these bulliten boards and I suspect they lose more money than they make. Ignore them and do your own research.

Good luck!

[wigwammer] 04/10/2019 09:13

RENE 3-5 bagged off an all time low of 50p. The price is significantly less than half of the £5 issue price of a few years back. That was one of the largest biotech issues globally that year - their technology is taken seriously. I don't agree that no material progress has been made. The very point they hit obstacles demonstrates the barriers that will exist to developing a competing product to Reneuron's. How many obstacles have they jumped? A marketable cryopreserved formulation - tick. Low cost of sales - tick. Clear signal of efficacy - tick. They now have the advantage of knowing that the treatment is likely to work best in patients with more mature RP and less retina damage. The whole point of a ph2a is to build knowledge to better construct a 2b and 3 trial that will get a positive result. I don't think it will take 10 years - it has orphan status and fast tracking. Regarding latest "damning" evidence - at 6 months the mean result was nearly 6 lines lower on a reading chart. I suspect they are nearer to getting a major deal than they have been in their history, and they care very close last year. ATB :)

[eggy6198] 04/10/2019 09:07

It already has fast track status but you know that already dont you. I believe 3 years with no issues is the release to market and sctually the take over. 10 years PLUS is based on one fact you want share price to drop. Just feeding a troll at this point

[scubadiverr] 04/10/2019 08:56

Have read read up on what's required to obtain a license to sell the product? Check and I think you will conclude Rene is considerable time away from even contemplating meeting the threshold. Alternatively you can keep dreaming, but please don't pretend your views are informed

[eggy6198] 04/10/2019 08:51

Sorry read this morning 10 years + for product when we are actually on human trials. Now i reading cash flow issies when there are none. I mean where they come from it was all looking good and still is and werid price action and deramping is occuring

[stewart_25] 04/10/2019 08:34

not forgetting the £80m fosun deal paid over time...

[marwalker] 04/10/2019 08:33

This is the morning of the third day of selling by those who don't like the results or just panicked into selling. These people must have completed acting on their views.

I'm buying a few ..... not sure what the clinical outcome will be ( who does ?)but looking for a bounce.

[s1zematters] 04/10/2019 08:33

i would have thought over stating the cash position by £7 million could be seen as more "desperate" than me posting actual facts Peggy?

[eggy6198] 04/10/2019 08:30

Wow size that is desperate

[s1zematters] 04/10/2019 08:22

"Cash, cash equivalents and bank deposits at 31 March 2019 of GBP26.4 million"


don't they spend over £1 million per month on admin and r&d
so that figure from March 19 is now nearer £19 million not £26 milion and falling every day!

aimho,

[scubadiverr] 04/10/2019 08:19

Feel free to counter my assumptions and understanding of clinical trials and bringing new treatments to market, ramper scum. 50p is where this was 6 months ago and it had 3-5 bagged until the latest damning set of published results on little material progress. Can this current price be justified? I feel not.

[rrb] 04/10/2019 08:16

it wont take that long to push through clinic. This is an unmet need and, if there is demonstrable efficacy (which data suggests there is), FDA will grant orphan drug status and it can be accelerated through to approval. Key is securing a partnership in the US and EU. This data release is open to interpretation and, for now, investors are clearly not willing to take risk. But at £45m mcap (£26m cash), this is a very cheap option.

[eggy6198] 04/10/2019 07:35

10p years away 10 years why fosum do deal? Deramping scum come in all forms... 50p? Greedy shorter

[scubadiverr] 03/10/2019 19:48

A game changing asset is likely 10+ years away. The trial is only phase I/IIa. You've then got further phase 2s before it will proceed to the important phase 3, if the treatment shows good efficacy and if the toxicity profile appears favourable. 2 patients out the considerably small sample have already suffered eye injuries to my understanding. The phase 3 would likely take 5+ years to yield results and then any marketing authorisation submission and approval would further increase the wait before the treatment will bring in any cashflow. Until then it's significant R&D cost. However noble medical advancements are far from certain in this industry and the market now seems to realise the price was inflated purely down to misplaced stem cell sentiment. I will keep checking and if I can buy at 50p I shall buy for my retirement.

[king1pin2] 03/10/2019 17:14

lol the trend was just short of £3.00 after the rns .

[costax1654x] 03/10/2019 16:43

Below 100 if it keeps the trend

[dickbush] 03/10/2019 16:39

Thanks, wigwammer for the information on Eylea and Lucentis. Very encouraging.

[wigwammer] 03/10/2019 16:08

S1ze has a point. If you're here long term it doesn't matter. I'm happy to stick it out, but then it's been one of my better calls... @310p..."30/4/2019 16:35 wigwammer: Tend to agree with rayrac - I have taken out my original investment at £3+ and happy to let the rest run. If we do have a game changing asset I will still be a very happy man :)"

[eggy6198] 03/10/2019 15:59

dont fancy eyla